Journal
ANTIOXIDANTS & REDOX SIGNALING
Volume 31, Issue 6, Pages 458-471Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2018.7649
Keywords
p62; SQSTM1; selective autophagy; cardiometabolic disease; cardiovascular disease; atherosclerosis; fatty liver disease
Funding
- NHLBI NIH HHS [F31 HL132434, R01 HL125838] Funding Source: Medline
- NIDDK NIH HHS [P30 DK020579] Funding Source: Medline
- BLRD VA [I01 BX003415] Funding Source: Medline
Ask authors/readers for more resources
Critical Issues: With the emergence of autophagy as a critical process in cellular metabolism and the development of cardiometabolic diseases, it is increasingly important to understand p62's role in the integration of signaling and autophagic pathways. Recent Advances: This review first discusses the features that make p62/SQSTM1 an ideal chaperone in integrating signaling pathways with autophagy and details the current understanding of its diverse roles in selective autophagy processes. Distinct and overlapping roles of other chaperones with similar functions are then discussed in the context of p62/SQSTM1. Finally, the recent literature focusing on p62 and selective autophagy in metabolism and the spectrum of cardiometabolic diseases including atherosclerosis, fatty liver disease, and obesity is evaluated. Future Directions: A comprehensive understanding of the nuanced roles p62/SQSTM1 plays in mediating distinct autophagy pathways would provide new insights into the mechanisms of this critical degradative pathway. This will, in turn, facilitate our understanding of cardiovascular and cardiometabolic disease pathology and the development of novel autophagy-modulating therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available